More news from the health front, on a day when it’s a titch easier to be optimistic about stocks; Redwood Park, Calif.-based Biotricity Inc. (OTC:BTCY) has launched its innovative pain management product with CPM Centres for Pain Management, a subsidiary of NeuPath Health, Canada’s largest provider of chronic pain management services.
The company, which specializes in medical diagnostic and consumer healthcare technology, trumpets its first expansion into the larger chronic care/pain management market, where it hopes to address gaps in technology solutions for patient diagnosis and management.
Said CEO Dr. Waqaas Al-Siddiq, "The ability to commercially launch a product, with a partner like NeuHealth, gives us great confidence. This new product will provide incremental recurring revenue on a per user basis, similar to our current Bioflux platform technology, enabling us to drive revenue growth."
The company’s pain management product is comprised of a software suite with applications for both patients and physicians. Patients can track progress while quantifying and managing their pain.
Physicians are enabled to monitor patient progress remotely and intercede with treatment adjustments while gaining deeper insight into the interplay between pain management and treatment.
Shares in BTCY flourished 13 cents, or 11.6%, to $1.25, on volume of 67,000 shares.
